NOVARTIS
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
- Conditions
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2006-08-31
- Lead Sponsor
- Novartis
- Registration Number
- NCT00098189
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
- Conditions
- First Posted Date
- 2004-12-03
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 76
- Registration Number
- NCT00098046
- Locations
- ๐ต๐ฆ
Novartis Investigational Site, David, Chiriqui, Panama
๐บ๐ธColumbia University Medical Center, New York, New York, United States
Sandostatin LARยฎ Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
- Conditions
- First Posted Date
- 2004-10-15
- Last Posted Date
- 2009-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 160
- Registration Number
- NCT00094146
- Locations
- ๐บ๐ธ
University of Wisconsin Beers-Murphy Clinical Nutrition Clinic, Madison, Wisconsin, United States
๐บ๐ธNew Orleans Center for Clinical Research, New Orleans, Louisiana, United States
๐บ๐ธUniversity of Tennessee, Memphis, Tennessee, United States
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00003884
- Locations
- ๐บ๐ธ
Cancer Specialist of South Texas. P.A., Corpus Christi, Texas, United States
๐บ๐ธNew England Medical Center Hospital, Boston, Massachusetts, United States
๐บ๐ธAmerican Medical Research Institute, Inc., Atlanta, Georgia, United States
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006343
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 89
- Registration Number
- NCT00006269
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
๐บ๐ธTheradex, Princeton, New Jersey, United States
STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
- Conditions
- First Posted Date
- 2004-05-04
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006053
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006475
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2014-01-31
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006052
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Novartis
- Registration Number
- NCT00014638
- Locations
- ๐บ๐ธ
Cancer Research Network, Inc., Hollywood, Florida, United States
๐บ๐ธGood Samaritan Medical Center, West Palm Beach, Florida, United States
๐บ๐ธCarle Cancer Center, Urbana, Illinois, United States